Instil Bio, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Instil Bio, Inc. (TIL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $17.58 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-27
- Instil Bio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $7.07.
- Instil Bio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $17.58, a 39.77% decline from fiscal 2024.
- Instil Bio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $29.19, a 130.21% increase from fiscal 2023.
- Instil Bio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $12.68, a 91.95% decline from fiscal 2022.
- Instil Bio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $157.48, a 1481.12% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $17.58 10-K · filed 2026-03-27 | ||||
| 2024-12-31 | $29.19 10-K · filed 2026-03-27 | ||||
| 2023-12-31 | $12.68 10-K · filed 2025-03-04 | ||||
| 2022-12-31 | $157.48 10-K · filed 2024-03-21 | $7.87 10-K · filed 2023-03-31 | |||
| 2021-12-31 | $9.96 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $9.57 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $9.25 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $7.07 10-Q · filed 2021-05-13 | ||||
| 2020-12-31 | $1.05 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |